Pfizer Sees Obesity Drugs Echoing Viagras Early Growth, CEO Says

Date:

Pfizer CEO Albert Bourla in Davos, Switzerland, on May 25, 2022. Fabrice Coffrini/AFPPfizer is gearing up for a consumer-driven market for obesity drugs that could match the rapid growth it experienced after introducing erectile dysfunction drug Viagra more than 20 years ago, Chief Executive Albert Bourla said on Jan. 12.Speaking during the J.P. Morgan Healthcare Conference in San Francisco, Bourla said Pfizer underestimated how quickly patients would be willing to pay out of pocket for obesity treatments, even without insurance coverage.

spot_imgspot_imgspot_img

Share post:

More like this
Related

26 Employees Sue Meta, Allege Unfair AI Selection for Layoffs

Twenty-six current and former employees of Meta are suing...

US Producer Inflation Unexpectedly Falls in June

Producer prices unexpectedly declined in June, driven primarily by...

Seattle Seahawks Sell to Khosla Family for $9.6 Billion

Vinod Khosla, Founder of Khosla Ventures, speaks onstage during...

Earnings Reports Start Soon, and They Should Be Spectacular

The Taiwan Semiconductor Manufacturing Company Ltd. (TSMC) headquarters in...